��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 0, () 343-345 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��м��
	�Ŵ�ҩ��ѧ
	��
	Ϳ��
	��
	PubMed
	Article by TU Hong-qin
	Article by LI Xin-yu

ҩ��ѧ��м��ҩ��Ĺ�ϵ

Ϳ��, ��

�й�ҽѧ��ѧԺƤ��о��, 210042

ժҪ��

��м��ǳ��Ը��Ƥ��֮һ,��ҩ��෱��,�Բ�ͬ��Ч��ҩ�ﶾ��ø��졣��м��ص�ҩ��ѧ�о��Ǵӻ��ˮƽ��ʶ��ҩ��õĸ��,�о�ҩ��Ч�Ͳ��Ӧ�ڲ�ͬ��Ĳ��̬�ԵĹ�ϵ,��Ч��Ч,�Լ�Ԥ��ҩ��Щ��п��ܷ��Է�Ӧ��м��ҩ��άA��ࡢά��D3���װ��ʡ��ص��ص�ҩ��ѧ�о��Ӧ�ÿ�ʹ��м��Ƹ��廯��

�ؼ���� м�� Ŵ�ҩ��ѧ

Relationship between pharmacogenomics and psoriasis medications

Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing 210042, China

Abstract:

Psoriasis is one of the most common chronic recurrent dermatoses. There are a variety of drugs to deal it with different effects and side effects on different patients. Pharmacogenomic research is to distinguish the individual variation in disease and drug effects at the level of genome, to study the relation between the individual difference in drug effects and side effects and genetic polymorphism, so as to distinguish effective and ineffective drugs and to anticipate possible toxic reaction in certain populations. The pharmacogenomic study about drugs in psoriasis treatment, such as retinoins, VitD3 analogues, methotrexate and cyclosporine, may lead to rationalization and individualization of psoriasis therapy.

Keywords: Psoriasis Pharmacogenetics

�ո�� 2007-07-16 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Evans WE,McLeod HL.Pharmacogenomics--drug disposition,drug targets,and side effects.N Engl J Med,2003,348(6):538-549.
[2] Meyer UA.Pharmacogenetics and adverse drug reactions Lancet,2000,356(9242):1667-1671.
[3] Mehl B,Santell JP.Projecting future drug expenditures.Am J Health Syst Pharm,2000,57(2):129-138.
[4] Vasku V,Bienertova Vasku J,Pavkova Goldbergova M,et al.Three retinoid X receptor gene polymorphisms in plaque psoriasis and psoriasis guttata.Dermatology,2007,214(2):118-124.
[5] Summers AM,Coupes BM,Brennan MF,et al.VEGF-460 genotype plays an important role in progression to chronic kidney disease stage 5.Nephrol Dial Transplant,2005,20(11):2427-2432.
[6] Young HS,Summers AM,Read IR,et al.Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.J Invest Dermatol,2006,126(2):453-459.
[7] Mathieu C,van Etten E,Decallonne B,et al.Vitamin D and 1,25-dihvdroxyvitamin D3 as modulators in the immune system.J Steroid Biochem Mol Biol,2004,89-90(1-5):449-452.
[8] Saeki H,Asano N,Tsunemi Y,et al.Polymorphisms of vitamin Dreeeptor gene in Japanese patients with psoriasis vulgaris.J Dermatol Sci,2002,30(2):167-171.
[9] Halsall JA,Osborme JE,Pringle JH,et al.Vitamin D receptor gene polymorphisms,particularly the novel A-1012G promoter polymorphism,are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis.Pharmacogenet Genomics,2005,15(5):349-355.
[10] Warren RB,Griffiths CE.The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.Br J Dermatol,2005,153(5):869-873.
[11] Kim RJ,Becker RC.Association between factor V Leiden,prothrombin G20210A,and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system:a meta-analysis of published studies.Am Heart J,2003,146(6):948-957.
[12] Kremer JM.Toward a better understanding of methotrexate.Arthritis Rheum,2004,50(5):1370-1382.
[13] Hughes LB,Beasley TM,Patel H,et al.Racial or ethnic differences in allele frequencies of single-nueleotide polymorphisms in the methylenetetrahydrofolate reduetase gene and their influence on response to methotrexate in rheumatoid arthritis.Ann Rheum Dis,2006,65(9):1213-1218.
[14] van Ede AE,Laan RF,Blom HJ,et al.The C677T mutation in the methylenetetrahydrofolate reductase gene:a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.Arthritis Rheum,2001,144(11):2525-2530.
[15] Kumagai K,Hiyama K,Oyama T,et al.Polymorphisms in thethymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.Int J Mol Med,2003,11(5):593-600.
[16] Dervieux T,Furst D,Lein DO,et al.Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier,aminoimidazole carboxamide ribonucleotide transformylase,and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.Arthritis Rheum,2004,50(9):2766-2774.
[17] Weisman MH,Furst DE,Park GS,et al.Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis.Arthritis Rheum,2006,54(2):607-612.
[18] Hu YF,Qiu W,Liu ZQ,et al.Effects of genetic polymorphisms of CYP3A4,CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.Clin Exp Pharmacol Physiol,2006,33(11):1093-1098.
[19] Hesselink DA,van Schaik RH,van der Heiden IP,et al.Genetic polymorphisms of the CYP3A4,CYP3A5,and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and taerolimus.Clin Pharmacol Ther,2003,74(3):245-254.